Granted Patent
B2
US 7,601,837 · App. 12/205,079 · Granted Oct 13, 2009
Quinoline derivatives and their use as 5-HT6 ligands
Assignee:
Glaxo Group Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
Claims (3)
1. A crystalline form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline, wherein said crystalline form provides an X-ray powder diffraction pattern substantially in accordance with FIG. 3 .
2. A crystalline form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline, wherein said crystalline form provides a Raman spectrum substantially in accordance with FIG. 2 .
3. A crystalline form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline, wherein said crystalline form provides an infra red spectrum substantially in accordance with FIG. 1 .
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 20, 2016
From: AHMED, MAHMOOD; JOHNSON, CHRISTOPHER NORBERT; JONES, MARTIN C.; MACDONALD, GREGOR JAMES; MOSS, STEPHEN FREDERICK; THOMPSON, MERVYN; WADE, CHARLES EDWARD; WITTY, DAVID R.
To: GLAXO GROUP LIMITED
Reel/Frame 040681/0300 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 20, 2016
From: AXOVANT SCIENCES LTD.
To: AXOVANT SCIENCES GMBH
Reel/Frame 041033/0327 →
CHANGE OF NAME
Recorded Apr 17, 2015
From: ROIVANT NEUROSCIENCES LTD.
To: AXOVANT SCIENCES LTD.
Reel/Frame 035455/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 5, 2015
From: GLAXO GROUP LIMITED
To: ROIVANT NEUROSCIENCES LTD.
Reel/Frame 034898/0900 →
Priority Claims (2)
GB 0207289.0
· Mar 27, 2002
· national
GB 0225678.2
· Nov 4, 2002
· national
Continuity (2)
Continuation
1050907800